title: Nab-paclitaxel and trastuzumab combination: a promising approach for neoadjuvant treatment in HER2-positive breast cancer.
abstract: Neoadjuvant therapy is a well-established approach for the treatment of locally advanced or inflammatory breast cancer (BC) and has been increasingly used in recent years not only as a management strategy but also as a research tool. Recently, nanoparticle albumin-bound paclitaxel (nab-paclitaxel)/trastuzumab combinations have been associated with promising activity in different clinical settings. In the present case, we report a complete pathological response after neoadjuvant treatment with the trastuzumab/nab-paclitaxel combination in a locally advanced human epidermal growth factor receptor 2 (HER2)-positive BC patient, with a good toxicity profile. This combination may represent a valid therapeutic option in the neoadjuvant therapy for HER2-positive locally advanced BC.
authors: Human Pathology University Department & Medical Oncology Unit AO Papardo, Messina, Italy.
authors: Giuseppina Rosaria Rita
authors: GR
authors: Ricciardi
authors: Human Pathology University Department & Medical Oncology Unit AO Papardo, Messina, Italy.
authors: Tindara
authors: T
authors: Franchina
authors: Human Pathology University Department & Medical Oncology Unit AO Papardo, Messina, Italy.
authors: Alessandro
authors: A
authors: Russo
authors: Human Pathology University Department & Medical Oncology Unit AO Papardo, Messina, Italy.
authors: Silvia
authors: S
authors: Schifano
authors: Human Pathology University Department & Medical Oncology Unit AO Papardo, Messina, Italy.
authors: Giuseppa
authors: G
authors: Ferraro
authors: Human Pathology University Department & Medical Oncology Unit AO Papardo, Messina, Italy.
authors: Vincenzo
authors: V
authors: Adamo
keywords: HER2-positive; breast cancer; nab-paclitaxel; neoadjuvant therapy; pathologic complete response; trastuzumab